REVIEW article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1652551
This article is part of the Research TopicTailored Strategies for Lung Cancer Diagnosis and Treatment in Special PopulationsView all 16 articles
Balancing Oncological Control and Immune Preservation in the Immunotherapy Era: Revisiting Lymph Node Dissection in Non-Small Cell Lung Cancer
Provisionally accepted
- Lanzhou University Second Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Systematic lymph node dissection (SLND) has long been widely accepted and established as a standard surgical procedure for lung cancer. In recent years, with the increased detection rate of early-stage non-small cell lung cancer (NSCLC) and the advancement of minimally invasive surgery and enhanced recovery concepts, approaches to lymph node dissection have undergone a notable shift. Previous studies have indicated that extensive removal of non-metastatic lymph nodes may offer uncertain clinical benefits. As a result, alternative strategies such as lobe-specific lymph node dissection (L-SLND) and lymph node sampling have gained attention among thoracic surgeons. In recent years, neoadjuvant chemoimmunotherapy for NSCLC has achieved remarkable success, with tumor-draining lymph nodes (TdLNs) playing a pivotal role in the efficacy of immunotherapy. Lymph node preservation strategies may synergize with immunotherapy by maintaining systemic immune surveillance. Conversely, the removal of non-metastatic lymph nodes could disrupt systemic immunity and exert secondary effects on primary tumors or potential micrometastases. This review summarizes the evolution of lymph node dissection strategies in lung cancer surgery and, in the context of encouraging outcomes with immunotherapy, provides new perspectives on future directions for balancing oncological control with immune preservation.
Keywords: Non-small cell lung cancer, tumor-draining lymph nodes, Neoadjuvant Therapy, Immunotherapy, Lymphadenectomy
Received: 23 Jun 2025; Accepted: 26 Sep 2025.
Copyright: © 2025 Jing, Yang, Wei, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bin Li, leebin@lzu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.